VSTM
Verastem, Inc. Health Care Pharmaceutical Preparations Russell 3000
$9.75Close
$758.0MMarket cap
$3.45 – $10.6452-week range
Nov 5, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 94 · stronger than 94% of stocks over 12 months
Cautions
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
8%
1wk
down 2.9%
price change
1mo
up 21.1%
price change
12-month return
up 6%
market up 11% ·
its own 0%
F-score
—
— Not assessed
Altman Z
-5.63
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
13.3×
price / book
Earnings yield
down 30.8%
EBIT / enterprise value
Cheaper than
6%
of the market · expensive
Revenue growth
up 209%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 366%
return on equity
Free cash margin
down 445%
-$137.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Trade setup
ATR%
6.8%
$0.67 a day · 2×ATR $8.42
RS
94 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
1.40
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 73.6% over the year, from 45m to 78m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Oct 14, 2026
Results reaction
Oct 14, 2026+25% vs market2 sessions after results
Financials
- Net -678%
- Free cash -445%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $88.5M | $2.1M | $2.6M | — | $10.0M | $30.9M |
| Operating income | -$49.4M | -$61.4M | -$72.9M | -$92.1M | -$115.0M | -$170.1M |
| Net income | -$67.7M | -$71.2M | -$73.8M | -$87.4M | -$130.6M | -$209.5M |
| Net margin | -77% | -3468% | -2843% | — | -1306% | -678% |
| Earnings per share | -$441.70 | -$4.90 | -$4.57 | -$3.96 | -$3.66 | -$3.02 |
| Free cash flow | -$33.5M | -$53.7M | -$63.7M | -$86.5M | -$104.8M | -$137.5M |
| Free cash margin | -38% | -2616% | -2453% | — | -1048% | -445% |
| Cash | $67.8M | $21.3M | $74.9M | $77.9M | $88.8M | $205.0M |
| Long-term debt | $0 | — | $24.5M | $40.1M | $40.7M | — |
| Shareholders' equity | $115.3M | $87.6M | $47.4M | $57.4M | -$28.9M | $57.2M |
| Shares outstanding | 170.46m | 185.29m | 16.71m | 25.28m | 44.78m | 77.74m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 4, 2026 | Annual ↗ | Dec 31, 2025 | 63d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Mar 20, 2025 | Annual ↗ | Dec 31, 2024 | 79d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 14, 2024 | Annual ↗ | Dec 31, 2023 | 74d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 14, 2026 | Other events ↗ |
| Oct 14, 2026 | Results · Director or officer change · Regulation FD · Other events ↗ |
| Aug 7, 2026 | Material agreement · New obligation · Regulation FD ↗ |
| Aug 6, 2026 | Results ↗ |
| Jun 23, 2026 | Regulation FD · Other events ↗ |
| Jun 17, 2026 | Regulation FD · Other events ↗ |
| May 26, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Regulation FD ↗ |
| Mar 4, 2026 | Regulation FD ↗ |
| Feb 4, 2026 | Results · Regulation FD ↗ |
| Jan 8, 2026 | Regulation FD ↗ |
| Dec 31, 2025 | Regulation FD · Other events ↗ |